Welcome to our dedicated page for IGM Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGM Biosciences filings document corporate-status and capital-structure matters for the company's common stock. Recent records include Form 25 removal of the common stock from Nasdaq listing and registration and Form 15 termination of registration or suspension of Exchange Act reporting duties for the same class of securities.
The filing record also includes an 8-K reporting a material definitive agreement, securities registered under Section 12(b), and public-company disclosures tied to governance, stockholder communications, and changes in the company's office-lease arrangements. These documents frame IGMS through its common stock, reporting obligations, and formal corporate-status disclosures.
IGM Biosciences (IGMS) Principal Accounting Officer Steven Weber reported a sale of 486 shares of common stock on June 16, 2025. The transaction was executed at a weighted average price of $1.1992 per share, with individual trades ranging from $1.17 to $1.22.
Key details of the transaction:
- The sale was specifically conducted to cover tax withholding obligations related to the vesting of restricted stock units
- Following the transaction, Weber maintains direct beneficial ownership of 26,530 shares
- The Form 4 was filed on June 28, 2025, with signature by power of attorney through Misbah Tahir
This transaction represents a routine share sale for tax purposes rather than a discretionary trading decision by the insider. The relatively small transaction size and its purpose suggest minimal significance for investor sentiment.